Dyslipidemia Market

Dyslipidemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

  • Rep Id : TMRGL1535
  • Published On : Aug 2015
  • No. of Pages : 101
  • Category : Pharmaceutical

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Sources
               1.3.1.1 Secondary Research
               1.3.1.2 Primary Research
               1.3.1.3 Assumption
1.4 List of Abbreviations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
2.2 Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
      2.2.1 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)
 
Chapter 3 Market Overview
3.1 Overview
3.2 Epidemiology: Dyslipidemia
3.3 Etiology of Dyslipidemia
      3.3.1 Primary Causes (genetic causes of dyslipidemia)
      3.3.2 Secondary Causes (lifestyle factors)
3.4 Dyslipidemia Diagnostics
      3.4.1 Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc.)
      3.4.2 Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc.)
      3.4.3 Secondary Causes Screening and Diagnostics
3.5 Trends and Future Aspects in Dyslipidemia Therapeutics (e.g. PCSK9, CETP inhibitors, etc.)
3.6 Market Dynamics
      3.6.1 Market Drivers
               3.6.1.1 Global increasing prevalence of population with cholesterol and triglyceride abnormalities expected to propel the market
               3.6.1.2 Rise in obese and diabetic populations is expected to increase the incidence of dyslipidemia, and thus demand for dyslipidemia drugs
               3.6.1.3 Extensive research and development changes bring turnaround changes in the dyslipidemia drugs market
               3.6.1.4 Rising disease awareness through promotional activities
      3.6.2 Market Restraints
               3.6.2.1 Impending patent expirations to deplete profit margins
               3.6.2.2 Discontinuation of novel dyslipidemia drugs
      3.6.3 Opportunities
               3.6.3.1 Expanding footprint in emerging nations to generate high sales growth
               3.6.3.2 Biological therapies for the treatment of dyslipidemia
               3.6.3.3 Development of molecules from newer class of dyslipidemia drugs provide a ladder for growth
               3.6.3.4 Strategic collaborations for new drug development
3.7 Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
3.8 Market Share by Key Players of Global Dyslipidemia Drugs Market, 2014 (Value %)
      3.8.1 Global Dyslipidemia Drugs Market Share Analysis, by Key Players, 2014 (%)
 
Chapter 4 Dyslipidemia Drugs Market, by Drug Class
4.1 Introduction
      4.1.1 Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 – 2023 (USD Million)
4.2 Statins
      4.2.1 Statins Market Revenue, 2013 – 2023 (USD Million)
4.3 Bile Acid Resins (Cholestyramine, Colestipol, Colesevelam, etc.)
      4.3.1 Bile Acid Resins Market Revenue, 2013 – 2023 (USD Million)
4.4 Fibric Acid and Omega-3 Fatty Acid Derivatives (Fenofibrate, Gemfibrozil, Vascespa, etc.)
     4.4.1 Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 – 2023 (USD Million)
4.5 Niacins (Niacor, Niaspan, Slo-Niacin, etc.)
      4.5.1 Niacins Market Revenue, 2013 – 2023 (USD Million)
4.6 Others (Combination drugs such as lovastatin and niacin, atorvastatin and amlodipine, simvastatin and ezetimibe, cholesterol absorption inhibitors, etc.)
      4.6.1 Others Market Revenue, 2013 – 2023 (USD Million)
4.7 Pipeline Drugs
     4.7.1 Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 – 2023 (USD Million)
      4.7.2 Anacetrapib (MK-0859)
              4.7.2.1 Anacetrapib Market Revenue, 2018 – 2023 (USD Million)
      4.7.3 Evacetrapib (LY2484595)
              4.7.3.1 Evacetrapib Market Revenue, 2017 – 2023 (USD Million)
      4.7.4 Praluent (Alirocumab)
              4.7.4.1 Praluent Market Revenue, 2015 – 2023 (USD Million)
      4.7.5 Evolocumab (Repatha)
              4.7.5.1 Evolocumab Market Revenue, 2015 – 2023 (USD Million)
      4.7.6 Bococizumab (RN316)
              4.7.6.1 Bococizumab Market Revenue, 2019 – 2023 (USD Million)
 
Chapter 5 Dyslipidemia Drugs Market, by Geography
5.1 Overview
      5.1.1 Dyslipidemia Drugs Market Revenue, by Geography, 2013 – 2023 (USD Million)
5.2 North America
      5.2.1 North America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.3 Europe
      5.3.1 Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.4 Asia Pacific
      5.4.1 Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.5 Latin America
      5.5.1 Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.6 Middle East and Africa
      5.6.1 Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
 
Chapter 6 Recommendations
6.1 Developing combination drugs for the treatment of dyslipidemia
6.2 Major research-based drug developing companies must collaborate with hospitals or acquire pharma establishments to develop more effective dyslipidemia treatments
6.3 Global players should target low to medium income countries to generate higher revenues
 
Chapter 7 Company Profiles
7.1 Abbott Laboratories
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 AstraZeneca plc
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Amgen, Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Bayer AG
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Bristol-Myers Squibb Company
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Mylan N.V.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Novartis AG
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 Merck & Co., Inc.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Pfizer, Inc.
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments
7.10 Shionogi & Co., Ltd.
      7.10.1 Company Overview
      7.10.2 Financial Overview
      7.10.3 Product Portfolio
      7.10.4 Business Strategies
      7.10.5 Recent Developments
7.11 Takeda Pharmaceutical Company Limited
      7.11.1 Company Overview
      7.11.2 Financial Overview
      7.11.3 Product Portfolio
      7.11.4 Business Strategies
      7.11.5 Recent Developments
7.12 Teva Pharmaceutical Industries Ltd.
      7.12.1 Company Overview
      7.12.2 Financial Overview
      7.12.3 Product Portfolio
      7.12.4 Business Strategies
      7.12.5 Recent Developments

List of Tables
 
TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
TABLE 3 Number of People with Diabetes (20 Years – 79 years), by Country/Territory, 2013 (Millions)
TABLE 4 Impact Analysis of Market Drivers
TABLE 5 Impact Analysis of Market Restraints
TABLE 6 Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 – 2023 (USD Million)
TABLE 7 Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 – 2023 (USD Million)
TABLE 8 Dyslipidemia Drugs Market Revenue, by Geography, 2013 – 2023 (USD Million)
TABLE 9 North America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 10 Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 11 Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 12 Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 13 Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)

List of Figures
 
FIG. 1 Dyslipidemia Drugs Market: Market Segmentation
FIG. 2 Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
FIG. 3 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)
FIG. 4 Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
FIG. 5 Global Dyslipidemia Drugs Market: Market Share, by Key Players, 2014 (%)
FIG. 6 Statins Market Revenue, 2013 – 2023 (USD Million)
FIG. 7 Bile Acid Resins Market Revenue, 2013 – 2023 (USD Million)
FIG. 8 Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 – 2023 (USD Million)
FIG. 9 Niacins Market Revenue, 2013 – 2023 (USD Million)
FIG. 10 Others Market Revenue, 2013 – 2023 (USD Million)
FIG. 11 Anacetrapib Market Revenue, 2018 – 2023 (USD Million)
FIG. 12 Evacetrapib Market Revenue, 2017 – 2023 (USD Million)
FIG. 13 Praluent Market Revenue, 2015 – 2023 (USD Million)
FIG. 14 Evolocumab Market Revenue, 2015 – 2023 (USD Million)
FIG. 15 Bococizumab Market Revenue, 2019 – 2023 (USD Million)
FIG. 16 Abbott Laboratories: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 17 AstraZeneca plc: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 18 Amgen, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 19 Bayer AG: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 20 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 21 Mylan N.V.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 22 Novartis AG: Annual Revenues, 2012 – 2014 (USD Million)
FIG. 23 Merck & Co., Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 24 Pfizer, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 25 Shionogi & Co., Ltd.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 26 Takeda Pharmaceutical Company Limited: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 27 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 – 2014 (USD Million)

.